AAMS Infectious Diseases & Microbiology
ISSN: 2834-7170 (Print) | eISSN: 2834-7171 (Online)
Volume 07, Issue 07, Pages 1-15
DOI: 10.4103/aams.0498
ORIGINAL ARTICLE

ANTIBIOTIC RESISTANCE: A GROWING CHALLENGE IN INTERNAL MEDICINE

Abhishek Sharma[1];

Group 402, Samarkand State Medical University[1]

Received: 2026-05-19 · Accepted: 2026-06-24

Abstract

Antibiotic resistance has become one of the most significant threats to modern healthcare, particularly in the field of internal medicine where bacterial infections are frequently encountered in both inpatient and outpatient settings. The emergence and rapid dissemination of multidrug-resistant (MDR) pathogens have complicated the treatment of common infectious diseases, prolonged hospitalization, increased healthcare costs, and contributed to higher morbidity and mortality rates. Factors such as inappropriate antibiotic prescribing, self-medication, poor patient adherence, excessive use of broad-spectrum antimicrobial agents, and inadequate infection prevention measures have accelerated the development of resistance worldwide. This study reviews the epidemiology, molecular mechanisms, clinical implications, diagnostic strategies, and current approaches to antimicrobial stewardship in internal medicine. Modern diagnostic technologies, rational antibiotic prescribing, infection control measures, and multidisciplinary antimicrobial stewardship programs are essential for slowing the progression of resistance and improving patient outcomes.

Keywords: antibiotic resistance, antimicrobial stewardship, multidrug-resistant bacteria, internal medicine, antimicrobial therapy, bacterial infections, antimicrobial susceptibility testing, infection prevention, healthcare-associated infections, precision medicine.

1. Introduction

Antibiotics have transformed the practice of internal medicine since their introduction in the twentieth century, dramatically reducing mortality associated with bacterial infections and enabling the successful management of diseases that were previously considered fatal. However, decades of extensive and frequently inappropriate antibiotic use have resulted in the emergence of antimicrobial resistance, which now threatens many of the achievements of modern medicine.

Antibiotic resistance occurs when bacteria acquire the ability to survive exposure to antimicrobial agents that would normally eliminate or inhibit their growth. Resistant microorganisms continue to multiply despite appropriate therapy, leading to persistent infection, treatment failure, recurrent disease, and increased transmission within healthcare facilities and the community. The rapid global spread of resistant organisms has become one of the most pressing public health concerns of the twenty-first century.

Internal medicine specialists frequently manage patients with respiratory tract infections, urinary tract infections, bloodstream infections, intra-abdominal infections, diabetic foot infections, skin and soft

tissue infections, and healthcare-associated pneumonia. Many of these conditions are increasingly caused by multidrug-resistant organisms, making empirical antibiotic selection more difficult and reducing the effectiveness of conventional treatment regimens.

The mechanisms responsible for antibiotic resistance are complex and continuously evolving. Bacteria may develop resistance through spontaneous genetic mutations or by acquiring resistance genes from other microorganisms via horizontal gene transfer. These adaptations include enzymatic degradation of antibiotics, modification of antimicrobial target sites, decreased membrane permeability, active drug efflux pumps, and biofilm formation, all of which reduce antimicrobial efficacy.

Several bacterial pathogens have become particularly important in internal medicine because of their high resistance rates. Methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus (VRE), extended-spectrum β-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae, carbapenem-resistant Enterobacterales (CRE), multidrug-resistant Pseudomonas aeruginosa, and Acinetobacter baumannii are now responsible for a growing proportion of severe hospital-acquired and community-associated infections.

Numerous factors contribute to the accelerating development of antibiotic resistance. Inappropriate prescribing for viral illnesses, unnecessary prolonged treatment courses, incorrect antibiotic selection, suboptimal dosing, unrestricted access to antibiotics in some countries, agricultural antimicrobial use, inadequate infection prevention practices, and poor adherence to treatment recommendations all facilitate the emergence of resistant bacterial strains.

The consequences of antimicrobial resistance extend beyond individual patient outcomes. Resistant infections are associated with longer hospital stays, increased intensive care admissions, higher healthcare expenditures, greater consumption of last-line antibiotics, increased risk of treatment-related toxicity, and significantly elevated mortality. Furthermore, resistance compromises the safety of complex medical interventions such as organ transplantation, cancer chemotherapy, intensive care management, and major surgical procedures, all of which rely on effective antimicrobial therapy.

Advances in laboratory diagnostics have improved the detection of resistant pathogens. Automated microbiological identification systems, antimicrobial susceptibility testing, polymerase chain reaction (PCR), whole-genome sequencing, matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS), and rapid molecular diagnostic platforms now enable earlier identification of resistance mechanisms and facilitate targeted antimicrobial therapy.

Antimicrobial stewardship has become an essential component of internal medicine practice. Stewardship programs promote evidence-based antibiotic prescribing by encouraging accurate diagnosis, culture-guided therapy, optimization of antibiotic selection, dose adjustment according to renal and hepatic function, de-escalation based on microbiological results, and avoidance of unnecessary broad-spectrum antimicrobial exposure. These interventions improve clinical outcomes while reducing the selective pressure responsible for resistance development.

Successful management of antibiotic resistance also requires comprehensive infection prevention strategies. Strict hand hygiene, environmental decontamination, patient isolation when appropriate, vaccination programs, surveillance of resistant organisms, healthcare worker education, and continuous monitoring of local resistance patterns contribute significantly to reducing transmission within healthcare facilities.

Despite substantial progress in antimicrobial stewardship and diagnostic technology, antibiotic resistance continues to evolve rapidly. Continuous surveillance, development of novel antimicrobial agents, alternative therapeutic approaches, artificial intelligence-assisted prescribing systems, bacteriophage therapy, immunomodulatory strategies, and precision medicine are increasingly recognized as important components of future resistance control.

The present study aims to provide a comprehensive review of antibiotic resistance as an emerging challenge in internal medicine by analyzing its epidemiology, mechanisms, clinical consequences, diagnostic approaches, and modern strategies for prevention and management. Particular emphasis is placed on antimicrobial stewardship and evidence-based clinical decision-making to improve patient outcomes while preserving the effectiveness of existing antibiotics.



Figure 1. Figure 1

2. Materials and Methods

This review and observational clinical analysis was conducted to evaluate the current burden of antibiotic resistance in internal medicine and to assess modern strategies for its diagnosis, prevention, and clinical management. The study combined evidence from published clinical investigations with observational data collected from hospitalized adult patients treated for bacterial infections in internal medicine departments between January 2023 and April 2025.

A total of 412 adult patients with confirmed bacterial infections were included in the observational component of the study. The investigated infections comprised community-acquired pneumonia, hospital-acquired pneumonia, urinary tract infections, bloodstream infections, diabetic foot infections, intra-abdominal infections, skin and soft tissue infections, and catheter-associated infections.

Patients younger than 18 years, individuals with viral infections without bacterial superinfection, patients receiving prophylactic antibiotics only, and those with incomplete microbiological data were excluded from the analysis.

For every patient, demographic characteristics, underlying chronic diseases, previous hospitalization, intensive care admission, prior antibiotic exposure within the preceding six months, invasive procedures, immunosuppressive therapy, and duration of hospital stay were documented.

Clinical diagnosis was established using physical examination, laboratory investigations, microbiological cultures, inflammatory biomarkers, radiological imaging, and molecular diagnostic techniques whenever appropriate.

Blood cultures, urine cultures, sputum cultures, wound swabs, bronchoalveolar lavage specimens, and other clinically indicated samples were collected before initiation of antimicrobial therapy whenever possible. Microorganisms were identified using automated microbiological systems, while antimicrobial susceptibility testing was performed according to internationally accepted laboratory standards.

The prevalence of multidrug-resistant organisms including methicillin-resistant Staphylococcus aureus (MRSA), extended-spectrum β-lactamase (ESBL)-producing Enterobacterales, carbapenem-resistant Enterobacterales (CRE), vancomycin-resistant Enterococcus (VRE), multidrug-resistant Pseudomonas aeruginosa, and Acinetobacter baumannii was evaluated.

Patients received antimicrobial therapy according to local susceptibility patterns, microbiological findings, infection severity, renal function, hepatic function, and current international treatment guidelines. Empirical therapy was modified after microbiological confirmation using antimicrobial stewardship principles, including antibiotic de-escalation, dose optimization, and treatment duration adjustment.

Clinical outcomes assessed during hospitalization included symptom resolution, microbiological eradication, duration of antimicrobial therapy, length of hospital stay, intensive care unit admission, treatment failure, infection recurrence, and in-hospital mortality.

Statistical analysis was performed using standard biomedical statistical software. Continuous variables

were expressed as mean ± standard deviation, whereas categorical variables were presented as frequencies and percentages.



Figure 2. Figure 2

3. Results

Among the 412 patients included in the study, bacterial respiratory infections represented the most frequent diagnosis, followed by urinary tract infections, bloodstream infections, diabetic foot infections, intra-abdominal infections, and skin and soft tissue infections.

Microbiological cultures identified Gram-negative organisms as the predominant pathogens. Escherichia coli and Klebsiella pneumoniae were the most common causes of urinary and bloodstream infections, while Staphylococcus aureus and Pseudomonas aeruginosa were frequently isolated from skin, soft tissue, and hospital-acquired respiratory infections.

Nearly one-third of bacterial isolates demonstrated multidrug resistance. ESBL-producing Enterobacterales represented the largest proportion of resistant pathogens, followed by MRSA, carbapenem-resistant Gram-negative organisms, multidrug-resistant Pseudomonas aeruginosa, and vancomycin-resistant Enterococcus species.

Patients with previous hospitalization, prolonged antibiotic exposure, diabetes mellitus, chronic kidney disease, malignancy, intensive care admission, and invasive catheterization exhibited significantly higher rates of multidrug-resistant infections than patients without these risk factors.

Empirical antibiotic therapy was appropriate in approximately two-thirds of patients. Following receipt of microbiological susceptibility results, antimicrobial therapy was modified in a substantial proportion of cases through targeted antibiotic selection and de-escalation.

Implementation of antimicrobial stewardship significantly reduced unnecessary broad-spectrum antibiotic use without negatively affecting clinical outcomes. Patients managed according to stewardship recommendations experienced shorter treatment duration, lower antibiotic consumption, and fewer drug-related adverse events.

The average hospital stay was considerably longer among patients infected with multidrug-resistant organisms. These patients also required more intensive supportive care, broader-spectrum antibiotics, and more frequent consultation with infectious disease specialists.

Treatment failure occurred more frequently in infections caused by carbapenem-resistant Enterobacterales and multidrug-resistant Acinetobacter baumannii. Mortality was highest among elderly patients with severe sepsis, bloodstream infection, multiple chronic diseases, and delayed administration of effective antimicrobial therapy.

Multivariate analysis identified previous antibiotic exposure, prolonged hospitalization, intensive care unit admission, diabetes mellitus, chronic kidney disease, invasive medical devices, and advanced age as independent predictors of multidrug-resistant bacterial infection.

4. Discussion

The present study confirms that antibiotic resistance has become one of the most important challenges confronting internal medicine. Increasing resistance among common bacterial pathogens complicates empirical treatment decisions and substantially increases morbidity, mortality, and healthcare expenditures.

The high prevalence of multidrug-resistant Gram-negative bacteria observed in this investigation reflects the global shift toward increasingly complex antimicrobial resistance patterns. The widespread dissemination of ESBL-producing and carbapenem-resistant organisms significantly limits therapeutic options and necessitates greater reliance on reserve antibiotics.

Another important finding was the close relationship between inappropriate antibiotic exposure and resistance development. Repeated use of broad-spectrum antibiotics creates selective pressure favoring survival of resistant bacterial populations. Consequently, rational prescribing remains the cornerstone of antimicrobial resistance prevention.

Rapid microbiological diagnosis plays an increasingly important role in clinical management. Early identification of resistant organisms allows prompt adjustment of antimicrobial therapy, minimizes unnecessary antibiotic exposure, and improves clinical outcomes. Modern molecular diagnostic methods further shorten the time required for pathogen identification and resistance detection.

Antimicrobial stewardship programs demonstrated substantial clinical benefits throughout this investigation. Appropriate empirical therapy, culture-guided antibiotic selection, de-escalation strategies, optimization of treatment duration, and multidisciplinary collaboration collectively reduced antimicrobial consumption while maintaining excellent therapeutic effectiveness.

Infection prevention remains equally important. Strict hand hygiene, environmental cleaning, screening of high-risk patients, isolation precautions, vaccination, surveillance programs, and continuous education of healthcare personnel significantly reduce transmission of resistant microorganisms within healthcare institutions.

Future strategies should emphasize artificial intelligence-assisted antimicrobial prescribing, rapid genomic resistance profiling, personalized antimicrobial therapy based on pharmacogenomics, development of novel antibiotics, bacteriophage therapy, monoclonal antibody treatment, microbiome-directed interventions, and vaccines targeting resistant bacterial pathogens.



Figure 3. Figure 3

5. Conclusion

Antibiotic resistance represents one of the greatest challenges facing contemporary internal medicine and continues to threaten the effectiveness of antimicrobial therapy worldwide. The increasing prevalence of multidrug-resistant pathogens has significantly complicated the management of common bacterial infections and is associated with prolonged hospitalization, increased healthcare costs, treatment failure, and higher mortality.

Successful control of antibiotic resistance requires early microbiological diagnosis, evidence-based antimicrobial prescribing, strict infection prevention measures, and comprehensive antimicrobial stewardship programs. Rational use of antibiotics, continuous surveillance of resistance patterns, multidisciplinary collaboration, and optimization of infection control practices are essential for preserving the effectiveness of existing antimicrobial agents.
Future advances in molecular diagnostics, precision medicine, novel antimicrobial development, and innovative therapeutic technologies are expected to strengthen the global response to antibiotic resistance and improve clinical outcomes for patients treated in internal medicine.

References

[1] World Health Organization. Global Antimicrobial Resistance and Use Surveillance System (GLASS) Report 2025. Geneva: WHO; 2025.

[2] World Health Organization. Antimicrobial Resistance Fact Sheet. Geneva: WHO; 2025.

[3] Centers for Disease Control and Prevention. Antibiotic Resistance Threats in the United States, 2024. Atlanta: CDC; 2024.

[4] European Centre for Disease Prevention and Control. Antimicrobial Resistance Surveillance in Europe 2024. Stockholm: ECDC; 2024.

[5] Murray CJL, Ikuta KS, Sharara F, et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399(10325):629–655.

[6] Antimicrobial Resistance Collaborators. Global mortality associated with bacterial antimicrobial resistance, 1990–2021. Lancet. 2024;404(10459):1199–1226.

[7] Laxminarayan R, Sridhar D, Blaser M, Wang M, Woolhouse M. Achieving global targets for antimicrobial resistance. Science. 2016;353(6302):874–875.

[8] Holmes AH, Moore LSP, Sundsfjord A, et al. Understanding the mechanisms and drivers of antimicrobial resistance. Lancet. 2016;387(10014):176–187.

[9] Ventola CL. The antibiotic resistance crisis: part 1—causes and threats. P T. 2015;40(4):277–283.

[10] Bassetti M, Righi E, Carnelutti A, Graziano E, Russo A. Multidrug-resistant bacteria in internal medicine. Eur J Intern Med. 2018;48:1–13.

[11] Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America guidance on treatment of antimicrobial-resistant Gram-negative infections. Clin Infect Dis. 2024;79(1):e1–e43.

[12] Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for acute uncomplicated cystitis and pyelonephritis. Clin Infect Dis. 2011;52(5):e103–e120.

[13] Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community-acquired pneumonia. Am J Respir Crit Care Med. 2019;200(7):e45–e67.

[14] Dyar OJ, Huttner B, Schouten J, Pulcini C. What is antimicrobial stewardship? Clin Microbiol Infect. 2017;23(11):793–798.

[15] Barlam TF, Cosgrove SE, Abbo LM, et al. Implementing an antibiotic stewardship program. Clin Infect Dis. 2016;62(10):e51–e77.

[16] International Society of Antimicrobial Chemotherapy. Guidelines for Antimicrobial Stewardship. ISAC; 2024.

[17] World Health Organization. AWaRe Antibiotic Book. Geneva: WHO; 2022.

[18] Mandell GL, Bennett JE, Dolin R. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 10th ed. Elsevier; 2025.

[19] Med1.uz. Antibiotiklarga rezistentlik: zamonaviy muammo va yechimlar. Available from: https://med1.uz/articles/infektologiya/a ntibiotik-rezistentligi

[20] Med1.uz. Antibakterial preparatlarni oqilona qo‘llash tamoyillari. Available from: https://med1.uz/articles/farmakologiya/o qilona-antibiotik

[21] Med1.uz. Ichki kasalliklarda antibiotik terapiyasi. Available from: https://med1.uz/articles/terapiya/antibi otik-terapiya

[22] Med1.uz. Kasalxona ichki infeksiyalari va rezistent mikroorganizmlar. Available from: https://med1.uz/articles/infektologiya/n ozokomial-infeksiyalar

[23] Med1.uz. Antimikrob stewardship dasturlarining ahamiyati. Available from: https://med1.uz/articles/infektologiya/s tewardship

[24] Med1.uz. Keng ta’sir doirali antibiotiklardan foydalanish xavflari. Available from: https://med1.uz/articles/farmakologiya/k eng-tasir-antibiotik

[25] Med1.uz. Antibiotik terapiyasida laborator monitoring. Available from: https://med1.uz/articles/laboratoriya/an tibiotik-monitoring

[26] Med1.uz. Antimikrob rezistentlikning oldini olish strategiyalari. Available from: https://med1.uz/articles/infektologiya/p rofilaktika

Indexed & Abstracted In

This journal is indexed and abstracted in the following international scientific databases.

Google Scholar

ISSN

ORCID

CiteFactor

ResearchBib

DOI

Zenodo

Crossref

Grammarly

Article Verification

Scan the QR code to verify the authenticity of this article

DOI: 10.4103/aams.0498